{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:16:48Z","timestamp":1788779808904,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleura that is currently incurable due to the lack of an effective early diagnostic method and specific medication. The <jats:italic>CDKN2A<\/jats:italic> (<jats:italic>p16<\/jats:italic>) and <jats:italic>NF2<\/jats:italic> genes are both frequently mutated in MPM. To understand how these mutations contribute to MPM tumor growth, we generated NF2\/p16 double-knockout (DKO) cell clones using human MeT-5A and HOMC-B1 mesothelial cell lines. Cell growth and migration activities were significantly increased in DKO compared with parental cells. cDNA microarray analysis revealed differences in global gene expression profiles between DKO and parental cells. Quantitative PCR and western blot analyses showed upregulation of CD24 concomitant with increased phosphorylation of AKT, p70S6K, and c-Jun in DKO clones. This upregulation was abrogated by exogenous expression of NF2 and p16. <jats:italic>CD24<\/jats:italic> knockdown in DKO cells significantly decreased TGF-\u03b21 expression and increased expression of E-cadherin, an epithelial\u2013mesenchymal transition marker. CD24 was highly expressed in human mesothelioma tissues (28\/45 cases, 62%) and associated with the loss of NF2 and p16. Public data analysis revealed a significantly shorter survival time in MPM patients with high <jats:italic>CD24<\/jats:italic> gene expression levels. These results strongly indicate the potential use of CD24 as a prognostic marker as well as a novel diagnostic and therapeutic target for MPM.<\/jats:p>","DOI":"10.1038\/s41420-020-00364-1","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T11:05:09Z","timestamp":1605697509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma"],"prefix":"10.1038","volume":"6","author":[{"given":"Sivasundaram","family":"Karnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-2921","authenticated-orcid":false,"given":"Akinobu","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Lutfur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Nazmul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md","family":"Wahiduzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hanamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lam","family":"Quang Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Inoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-4905","authenticated-orcid":false,"given":"Hiroyuki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"364_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","volume":"69","author":"C Carbone","year":"2019","unstructured":"Carbone, C. et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J. Clin. 69, 402\u2013429 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"364_CR2","first-page":"63","volume":"7","author":"SC Patel","year":"2016","unstructured":"Patel, S. C. & Dowell, J. E. Modern management of malignant pleural mesothelioma. Lung Cancer 7, 63\u201372 (2016).","journal-title":"Lung Cancer"},{"key":"364_CR3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636\u20132644 (2003).","journal-title":"J. Clin. Oncol."},{"key":"364_CR4","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","volume":"11","author":"M Carbone","year":"2016","unstructured":"Carbone, M. et al. Consensus report of the 2015 Weinman International Conference on Mesothelioma. J. Thorac. Oncol. 11, 1246\u20131262 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"364_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.semdp.2006.08.002","volume":"23","author":"M Carbone","year":"2006","unstructured":"Carbone, M. & Bedrossian, C. W. The pathogenesis of mesothelioma. Semin. Diagn. Pathol. 23, 56\u201360 (2006).","journal-title":"Semin. Diagn. Pathol."},{"key":"364_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/carcin\/18.4.825","volume":"18","author":"H Fung","year":"1997","unstructured":"Fung, H., Kow, Y. W., Van, H. B. & Mossman, B. T. Patterns of 8 hydroxydeoxyguanosine formation in DNA and indications of oxidative stress in rat and human pleural mesothelial cells after exposure to crocidolite asbestos. Carcinogenesis 18, 825\u2013832 (1997).","journal-title":"Carcinogenesis"},{"key":"364_CR7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","volume":"34","author":"Y Sekido","year":"2013","unstructured":"Sekido, Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 34, 1413\u20131419 (2013).","journal-title":"Carcinogenesis"},{"key":"364_CR8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022\u20131025 (2011).","journal-title":"Nat. Genet."},{"key":"364_CR9","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 loss in malignant pleural mesothelioma. Nat. Genet. 43, 668\u2013672 (2011).","journal-title":"Nat. Genet."},{"key":"364_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","volume":"75","author":"G Guo","year":"2015","unstructured":"Guo, G. et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 75, 264\u2013269 (2015).","journal-title":"Cancer Res."},{"key":"364_CR11","first-page":"5547","volume":"54","author":"JQ Cheng","year":"1994","unstructured":"Cheng, J. Q. et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 54, 5547\u20135551 (1994).","journal-title":"Cancer Res."},{"key":"364_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","volume":"64","author":"C Thurneysen","year":"2009","unstructured":"Thurneysen, C. et al. Functional inactivation of NF2\/merlin in human mesothelioma. Lung Cancer 64, 140\u2013147 (2009).","journal-title":"Lung Cancer"},{"key":"364_CR13","doi-asserted-by":"publisher","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","volume":"92","author":"AB Bianchi","year":"1995","unstructured":"Bianchi, A. B. et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl Acad. Sci. USA 92, 10854\u201310858 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"364_CR14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","volume":"39","author":"BS Sheffield","year":"2015","unstructured":"Sheffield, B. S. et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am. J. Surg. Pathol. 39, 977\u2013982 (2015).","journal-title":"Am. J. Surg. Pathol."},{"key":"364_CR15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","volume":"47","author":"M Farzin","year":"2015","unstructured":"Farzin, M. et al. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology 47, 302\u2013307 (2015).","journal-title":"Pathology"},{"key":"364_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","volume":"10","author":"M Nasu","year":"2015","unstructured":"Nasu, M. et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J. Thorac. Oncol. 10, 565\u2013576 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"364_CR17","doi-asserted-by":"publisher","first-page":"13432","DOI":"10.1073\/pnas.1612074113","volume":"113","author":"Y Yoshikawa","year":"2016","unstructured":"Yoshikawa, Y. et al. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc. Natl Acad. Sci. USA 113, 13432\u201313437 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"364_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/cas.13871","volume":"110","author":"M Wahiduzzaman","year":"2019","unstructured":"Wahiduzzaman, M. et al. Establishment and characterization of CRISPR\/Cas9-mediated NF2(-\/-) human mesothelial cell line: molecular insight intofibroblast growth factor receptor 2 in malignant pleural mesothelioma. Cancer Sci. 110, 180\u2013193 (2019).","journal-title":"Cancer Sci."},{"key":"364_CR19","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","volume":"79","author":"AM Kukuyan","year":"2019","unstructured":"Kukuyan, A. M. et al. Inactivation of Bap1 cooperates with losses of Nf2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models. Cancer Res. 79, 4113\u20134123 (2019).","journal-title":"Cancer Res."},{"key":"364_CR20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1242\/jcs.02741","volume":"119","author":"H Schabath","year":"2006","unstructured":"Schabath, H., Runz, S., Joumaa, S. & Altevogt, P. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J. Cell. Sci. 119, 314\u2013325 (2006).","journal-title":"J. Cell. Sci."},{"key":"364_CR21","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/S0002-9440(10)64398-2","volume":"161","author":"G Kristiansen","year":"2002","unstructured":"Kristiansen, G. et al. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am. J. Pathol. 161, 1215\u20131221 (2002).","journal-title":"Am. J. Pathol."},{"key":"364_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/sj.bjc.6600702","volume":"88","author":"G Kristiansen","year":"2003","unstructured":"Kristiansen, G. et al. CD24 is an independent prognostic marker of survival in non-small cell lung cancer patients. Br. J. Cancer 88, 231\u2013236 (2003).","journal-title":"Br. J. Cancer"},{"key":"364_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08094-8","volume":"7","author":"DC Ayre","year":"2017","unstructured":"Ayre, D. C. et al. CD24 induces changes to the surface receptors of B cell microvesicles with variable effects on their RNA and protein cargo. Sci. Rep. 7, 8642 (2017).","journal-title":"Sci. Rep."},{"key":"364_CR24","doi-asserted-by":"publisher","first-page":"517172","DOI":"10.1155\/2012\/517172","volume":"2012","author":"J Deng","year":"2012","unstructured":"Deng, J. et al. CD24 expression as a marker for predicting clinical outcome in human gliomas. J. Biomed. Biotechnol. 2012, 517172 (2012).","journal-title":"J. Biomed. Biotechnol."},{"key":"364_CR25","first-page":"4906","volume":"9","author":"G Kristiansen","year":"2003","unstructured":"Kristiansen, G. et al. CD24 expression is a new prognostic marker in breast cancer. Clin. Cancer Res. 9, 4906\u20134913 (2003).","journal-title":"Clin. Cancer Res."},{"key":"364_CR26","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1245\/s10434-008-0252-0","volume":"16","author":"A Sano","year":"2009","unstructured":"Sano, A. et al. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann. Surg. Oncol. 16, 506\u2013514 (2009).","journal-title":"Ann. Surg. Oncol."},{"key":"364_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1159\/000079824","volume":"4","author":"J Jacob","year":"2004","unstructured":"Jacob, J. et al. Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology 4, 454\u2013460 (2004).","journal-title":"Pancreatology"},{"key":"364_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.canlet.2005.03.059","volume":"235","author":"MC Su","year":"2006","unstructured":"Su, M. C., Hsu, C., Kao, H. L. & Jeng, Y. M. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett. 235, 34\u201339 (2006).","journal-title":"Cancer Lett."},{"key":"364_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0681-z","volume":"9","author":"S Lu","year":"2018","unstructured":"Lu, S. et al. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. Cell Death Dis. 9, 646 (2018).","journal-title":"Cell Death Dis."},{"key":"364_CR30","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.3892\/or.2015.4257","volume":"34","author":"T Tanaka","year":"2015","unstructured":"Tanaka, T. et al. CD24 expression as a marker for predicting clinical outcome and invasive activity in uterine cervical cancer. Oncol. Rep. 34, 2282\u20132288 (2015).","journal-title":"Oncol. Rep."},{"key":"364_CR31","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.3892\/or.2017.5583","volume":"37","author":"K Nakamura","year":"2017","unstructured":"Nakamura, K. et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways. Oncol. Rep. 37, 3189\u20133200 (2017).","journal-title":"Oncol. Rep."},{"key":"364_CR32","doi-asserted-by":"publisher","first-page":"49156","DOI":"10.18632\/oncotarget.9402","volume":"7","author":"C Lubeseder-Martellato","year":"2016","unstructured":"Lubeseder-Martellato, C. et al. Membranous CD24 drives the epithelial phenotype of pancreatic cancer. Oncotarget 7, 49156\u201349168 (2016).","journal-title":"Oncotarget"},{"key":"364_CR33","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/bjc.2013.102","volume":"108","author":"AV Salnikov","year":"2013","unstructured":"Salnikov, A. V. et al. Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas. Br. J. Cancer 108, 1449\u20131459 (2013).","journal-title":"Br. J. Cancer"},{"key":"364_CR34","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal, A. A. et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572, 392\u2013396 (2019).","journal-title":"Nature"},{"key":"364_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1158\/1535-7163.MCT-18-0292","volume":"18","author":"SH Chan","year":"2019","unstructured":"Chan, S. H. et al. Identification of the novel role of CD24 as an oncogenesis regulator and therapeutic target for triple-negative breast cancer. Mol. Cancer Ther. 18, 147\u2013161 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"364_CR36","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2174\/1570163814666170818125036","volume":"18","author":"S Eyvazi","year":"2018","unstructured":"Eyvazi, S., Kazemi, B., Dastmalchi, S. & Bandehpour, M. Involvement of CD24 in multiple cancer related pathways makes it an interesting new target for cancer therapy. Curr. Cancer Drug Targets 18, 328\u2013336 (2018).","journal-title":"Curr. Cancer Drug Targets"},{"key":"364_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/B978-0-12-394311-8.00005-4","volume":"116","author":"AP Kowalczyk","year":"2013","unstructured":"Kowalczyk, A. P. & Green, K. J. Structure, function, and regulation of desmosomes. Prog. Mol. Biol. Transl. Sci. 116, 95\u2013118 (2013).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"364_CR38","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12253-016-0128-8","volume":"23","author":"D Arik","year":"2017","unstructured":"Arik, D., Can, C., D\u00fcndar, E., Kabuk\u00e7uo\u011flu, S. & Pa\u015fao\u011flu, \u00d6. Prognostic significance of CD24 in clear cell renal cell carcinoma. Pathol. Oncol. Res. 23, 409\u2013416 (2017).","journal-title":"Pathol. Oncol. Res."},{"key":"364_CR39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbrc.2012.02.054","volume":"419","author":"H Yamazaki","year":"2012","unstructured":"Yamazaki, H. et al. Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells. Biochem. Biophys. Res. Commun. 419, 529\u2013536 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"364_CR40","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney, D. G. et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 90, 2188\u20132195 (1997).","journal-title":"Blood"},{"key":"364_CR41","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00001622-199811000-00012","volume":"10","author":"GA Leget","year":"1998","unstructured":"Leget, G. A. & Czuczman, M. S. Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 10, 548\u2013551 (1998).","journal-title":"Curr. Opin. Oncol."},{"key":"364_CR42","first-page":"5","volume":"43","author":"N Aruga","year":"2018","unstructured":"Aruga, N. et al. Epithelial-mesenchymal transition (EMT) is correlated with patient\u2019s prognosis of lung squamous cell carcinoma. Tokai J. Exp. Clin. Med. 43, 5\u201313 (2018).","journal-title":"Tokai J. Exp. Clin. Med."},{"key":"364_CR43","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/mc.22644","volume":"56","author":"K Hutz","year":"2017","unstructured":"Hutz, K., Zeiler, J., Sachs, L., Ormanns, S. & Spindler, V. Loss of desmoglein 2 promotes tumorigenic behavior in pancreatic cancer cells. Mol. Carcinog. 56, 1884\u20131895 (2017).","journal-title":"Mol. Carcinog."},{"key":"364_CR44","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1158\/0008-5472.CAN-04-3398","volume":"65","author":"H Shiina","year":"2005","unstructured":"Shiina, H. et al. Functional loss of the \u03b3-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res. 65, 2130\u20132138 (2005).","journal-title":"Cancer Res."},{"key":"364_CR45","doi-asserted-by":"publisher","first-page":"R529","DOI":"10.1016\/j.cub.2011.04.035","volume":"21","author":"AD Dubash","year":"2011","unstructured":"Dubash, A. D. & Green, K. J. Desmosomes. Curr. Biol. 21, R529\u2013R531 (2011).","journal-title":"Curr. Biol."},{"key":"364_CR46","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/carcin\/bgw084","volume":"37","author":"T Kakiuchi","year":"2016","unstructured":"Kakiuchi, T. et al. Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation. Carcinogenesis 37, 1098\u20131109 (2016).","journal-title":"Carcinogenesis"},{"key":"364_CR47","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"364_CR48","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/cam4.1179","volume":"6","author":"M Yamaji","year":"2017","unstructured":"Yamaji, M. et al. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 6, 2646\u20132659 (2017).","journal-title":"Cancer Med."},{"key":"364_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2018.06.027","volume":"433","author":"M Wahiduzzaman","year":"2018","unstructured":"Wahiduzzaman, M. et al. Novel combined Ato-C treatment synergistically suppresses proliferation of bcr-abl-positive leukemic cells in vitro and in vivo. Cancer Lett. 433, 117\u2013130 (2018).","journal-title":"Cancer Lett."},{"key":"364_CR50","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/cas.13013","volume":"107","author":"T Ito","year":"2016","unstructured":"Ito, T. et al. Loss of YAP1 defines neuroendocrine differentiation of lung tumors. Cancer Sci. 107, 1527\u20131538 (2016).","journal-title":"Cancer Sci."}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-020-00364-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-020-00364-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-020-00364-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T16:12:01Z","timestamp":1670256721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-020-00364-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["364"],"URL":"https:\/\/doi.org\/10.1038\/s41420-020-00364-1","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"assertion":[{"value":"11 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"127"}}